CN112888711A - 基于flt3l的嵌合蛋白 - Google Patents

基于flt3l的嵌合蛋白 Download PDF

Info

Publication number
CN112888711A
CN112888711A CN201980068131.4A CN201980068131A CN112888711A CN 112888711 A CN112888711 A CN 112888711A CN 201980068131 A CN201980068131 A CN 201980068131A CN 112888711 A CN112888711 A CN 112888711A
Authority
CN
China
Prior art keywords
chimeric protein
cells
ser
domain
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980068131.4A
Other languages
English (en)
Chinese (zh)
Inventor
T·施赖伯
G·弗罗姆
S·达西瓦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shattuck Labs Inc
Original Assignee
Shattuck Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shattuck Labs Inc filed Critical Shattuck Labs Inc
Publication of CN112888711A publication Critical patent/CN112888711A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201980068131.4A 2018-08-29 2019-08-29 基于flt3l的嵌合蛋白 Pending CN112888711A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862724596P 2018-08-29 2018-08-29
US62/724,596 2018-08-29
PCT/US2019/048922 WO2020047327A2 (en) 2018-08-29 2019-08-29 Flt3l-based chimeric proteins

Publications (1)

Publication Number Publication Date
CN112888711A true CN112888711A (zh) 2021-06-01

Family

ID=69643788

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980068131.4A Pending CN112888711A (zh) 2018-08-29 2019-08-29 基于flt3l的嵌合蛋白

Country Status (9)

Country Link
US (1) US20240122983A1 (https=)
EP (1) EP3843755A4 (https=)
JP (2) JP2022512540A (https=)
CN (1) CN112888711A (https=)
AU (1) AU2019333175A1 (https=)
CA (1) CA3109352A1 (https=)
IL (1) IL281088A (https=)
MX (1) MX2021002289A (https=)
WO (1) WO2020047327A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20210687A (es) * 2019-06-25 2022-03-03 Gilead Sciences Inc PROTEÍNAS DE FUSIÓN FLT3L-Fc Y MÉTODOS DE USO
JP2023506501A (ja) * 2019-12-16 2023-02-16 ワシントン・ユニバーシティ キメラ抗原受容体樹状細胞（ｃａｒ－ｄｃ）ならびにこれを作製および使用する方法
WO2022089418A1 (zh) * 2020-10-26 2022-05-05 信达生物制药(苏州)有限公司 重组截短FLT3配体与人抗体Fc的融合蛋白
WO2024123812A1 (en) 2022-12-05 2024-06-13 Shattuck Labs, Inc. Fusion proteins for the treatment of cardiometabolic diseases

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101198621A (zh) * 2005-01-25 2008-06-11 阿波罗生命科学有限公司 分子及其嵌合分子
US8043608B2 (en) * 1999-07-21 2011-10-25 Merck Patent Gmbh Methods of using Fc-cytokine fusion proteins
CA2999280A1 (en) * 2015-10-01 2017-04-06 Heat Biologics, Inc. Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1276501B9 (en) * 2000-04-25 2007-01-24 Immunex Corporation Method for treatment of tumors using photodynamic therapy
MXPA03003632A (es) * 2000-10-24 2003-09-10 Immunex Corp Metodo para tratamiento de tumores usando terapia de combinacion.
WO2014043215A1 (en) * 2012-09-11 2014-03-20 The Texas A&M University System Bi-specifc diabodies for masking and targeting vaccines
JP6898325B2 (ja) * 2015-12-08 2021-07-07 ユニバーシティ−インダストリー・ファンデーション・ヨンセイ・ユニバーシティ ＧＭ−ＣＳＦ遺伝子；Ｆｌｔ３Ｌ−ＴＲＡＩＬ融合遺伝子；ＴＧＦ−βの発現を抑制するｓｈＲＮＡ；およびＨＳＰ発現を抑制するｓｈＲＮＡを含む抗腫瘍組成物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8043608B2 (en) * 1999-07-21 2011-10-25 Merck Patent Gmbh Methods of using Fc-cytokine fusion proteins
CN101198621A (zh) * 2005-01-25 2008-06-11 阿波罗生命科学有限公司 分子及其嵌合分子
CA2999280A1 (en) * 2015-10-01 2017-04-06 Heat Biologics, Inc. Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
CN108350055A (zh) * 2015-10-01 2018-07-31 热生物制品有限公司 作为异源嵌合蛋白邻接i型和ii型胞外结构域的组合物和方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
LUIS BORGES等: "Synergistic Action of fms-Like Tyrosine Kinase 3 Ligand and CD40 Ligand in the Induction of Dendritic Cells and Generation of Antitumor Immunity In Vivo", 《J IMMUNOL》, vol. 163, no. 3, pages 1289 *
XIAOFENG WU等: "Induction of Potent TRAIL-Mediated Tumoricidal Activity by hFLEX/Furin/TRAIL Recombinant DNA Construct", 《MOLECULAR THERAPY》, vol. 9, no. 5, pages 674 - 681, XP002412527, DOI: 10.1016/j.ymthe.2004.02.021 *
谈珉: "抗CD20抗体/Flt3L双功能融合蛋白的抗肿瘤作用机理研究", 《中国博士学位论文全文数据库医药卫生科技辑》, no. 9, pages 072 - 12 *
陈沁韵;万延民;张晓燕;: "IgG-Fc融合蛋白的研究进展", 中国生物制品学杂志, no. 11, pages 1223 - 1227 *

Also Published As

Publication number Publication date
CA3109352A1 (en) 2020-03-05
EP3843755A4 (en) 2022-08-31
WO2020047327A2 (en) 2020-03-05
JP2024096361A (ja) 2024-07-12
MX2021002289A (es) 2021-05-27
JP2022512540A (ja) 2022-02-07
IL281088A (en) 2021-04-29
US20240122983A1 (en) 2024-04-18
AU2019333175A1 (en) 2021-03-04
EP3843755A2 (en) 2021-07-07
WO2020047327A3 (en) 2020-07-23

Similar Documents

Publication Publication Date Title
JP7620045B2 (ja) Ｔｉｇｉｔ及びｌｉｇｈｔベースのキメラタンパク質
KR20180051651A (ko) 비상동성 키메라 단백질로서의 i형 및 ii형 세포외 도메인을 인접시키기 위한 조성물 및 방법
CN113747947A (zh) 组合疗法
US20240122983A1 (en) Flt3l-based chimeric proteins
CN112839952A (zh) 包含基于pd-1的嵌合蛋白的组合疗法
KR20190124247A (ko) Csf1r-기반 키메라 단백질
CN114126663A (zh) Nk细胞定向的嵌合蛋白
US11896618B2 (en) FLT3L-based chimeric proteins
CN110290798B (zh) 基于vsig8的嵌合蛋白
US20240299492A1 (en) Combination therapies with sirp alpha-based chimeric proteins
CN112912384A (zh) 组合疗法
WO2022187583A1 (en) Combination therapies with tim-3-based chimeric proteins
CN112888706A (zh) 包含基于tim-3的嵌合蛋白的组合疗法
RU2775490C2 (ru) Химерные белки на основе tigit и light
CN117355336A (zh) 基于SIRP α的嵌合蛋白的联合疗法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210601

WD01 Invention patent application deemed withdrawn after publication